The estimated Net Worth of Richard A. Heyman is at least $495 Thousand dollars as of 14 September 2021. Richard Heyman owns over 1,388 units of Gritstone Bio Inc stock worth over $105,973 and over the last 11 years he sold GRTS stock worth over $282,887. In addition, he makes $105,949 as Independent Director at Gritstone Bio Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Richard Heyman GRTS stock SEC Form 4 insiders trading
Richard has made over 9 trades of the Gritstone Bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,388 units of GRTS stock worth $34,756 on 14 September 2021.
The largest trade he's ever made was selling 5,874 units of Gritstone Bio Inc stock on 14 May 2021 worth over $148,553. On average, Richard trades about 522 units every 6 days since 2013. As of 14 September 2021 he still owns at least 216,272 units of Gritstone Bio Inc stock.
You can see the complete history of Richard Heyman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Heyman biography
Dr. Richard Heyman Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Dr. Heyman has served as a member of our board of directors since November 2015. Dr. Heyman is executive chairman of the board of directors and co-founder of Metacrine, Inc., a biotechnology company developing new therapeutics for the treatment of liver and gastrointestinal diseases. He also is the co-founder and chairman of the board of directors of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer. Previously, Dr. Heyman served as president and chief executive officer of Seragon Pharmaceuticals Inc., or Seragon, a privately-held biotechnology company, which was acquired by Genentech in 2014. Prior to Seragon, he co-founded and served as president and chief executive officer of Aragon Pharmaceuticals, Inc., or Aragon, until it was purchased by Johnson & Johnson in 2013. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the recently approved prostate cancer drug, Erleada. Dr. Heyman is a venture partner for Arch Ventures and also serves on the boards of directors for private life sciences companies Yumanity Therapeutics, Vividion Therapeutics and Amunix Inc. He is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the American Association for Cancer Research, or AACR, and on the executive committee at the University of California at San Diego Moores Cancer Center. He has won numerous awards including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award. Dr. Heyman received a B.S. in chemistry from the University of Connecticut and a Ph.D. in pharmacology from the University of Minnesota.
What is the salary of Richard Heyman?
As the Independent Director of Gritstone Bio Inc, the total compensation of Richard Heyman at Gritstone Bio Inc is $105,949. There are 9 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.
What's Richard Heyman's mailing address?
Richard's mailing address filed with the SEC is C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Gritstone Bio Inc
Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson, and Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.
What does Gritstone Bio Inc do?
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
What does Gritstone Bio Inc's logo look like?
Complete history of Richard Heyman stock trades at Organovo Inc, Gritstone Bio Inc, Oric Pharmaceuticals, Metacrine, and Pmv Pharmaceuticals Inc
Gritstone Bio Inc executives and stock owners
Gritstone Bio Inc executives and other stock owners filed with the SEC include:
-
Andrew Allen,
President, Chief Executive Officer, Director -
Jean-Marc Bellemin,
Chief Financial Officer, Executive Vice President -
Raphael Rousseau,
Executive Vice President, Chief Medical Officer -
Karin Jooss,
Executive Vice President - Research, Chief Scientific Officer -
Roman Yelensky,
Executive Vice President, Chief Technology Officer -
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.,
Co-Founder, Pres, CEO & Director -
Erin E. Jones M.S.,
Chief Operating Officer -
Steve Krognes,
Independent Director -
Thomas Woiwode,
Independent Director -
Richard Heyman,
Independent Director -
Judith Li,
Independent Director -
Nicholas Simon,
Independent Director -
Elaine Jones,
Chairman of the Board -
Vijay Yabannavar,
Executive Vice President, Manufacturing and Technical Operations -
Erin Jones,
Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance -
Matthew Hawryluk,
Executive Vice President, Chief Business Officer -
Alan C. Mendelson J.D.,
Sec. -
Dr. Karin Jooss,
Head of R&D -
Dr. Matthew Hawryluk,
Exec. VP & Chief Bus. Officer -
Prof. Raphael F. Rousseau M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Stacy Proctor,
Sr. VP & Head of People -
Rahsaan W. Thompson J.D.,
Exec. VP & Gen. Counsel -
James Cho,
Chief Accounting Officer -
Vassiliki Economides,
Exec. VP & CFO -
Stephen W Webster,
-
Group, Llc Green Jeremy Red...,
-
Venture Capital V, L.P.Vers...,
-
Peter Svennilson,
Director -
Group Ii, Lp Column Group I...,
-
Lifesciences Iii, L.P.Claru...,
-
Rahsaan Thompson,
EVP and General Counsel -
Shefali Agarwal,
-
Clare Fisher,
-
Naiyer Rizvi,
-
Lawrence Corey,
-
James Cho,
SVP, CHIEF ACCOUNTING OFFICER -
Vassiliki Economides,
EVP, CHIEF FINANCIAL OFFICER